Sponsored Links
| FDA Sets March 22 For ODAC Meeting To Review CTI's New Drug Application For Pixantrone |
 |
 |
 |
| Pharmacy - Pharma Industry - Biotech Industry | |||
|
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that the U.S. Food and Drug Administration's ("FDA") Oncologic Drugs Advisory Committee ("ODAC") will review CTI's New Drug Application ("NDA") for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") on March 22, 2010... Read more: Pharma Industry / Biotech Industry News From Medical News Today
|